title: Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma.
abstract: In an attempt to investigate the interaction between the changes of cytokines and acute phase reactants after transcatheter arterial chemoembolization therapy (TACE), the levels of interleukin 6 (IL-6), interleukin 8 (IL-8), C-reactive protein (CRP) and pancreatic secretory trypsin inhibitor (PSTI) in the blood of patients with unresectable hepatocellular carcinoma (HCC) were measured. Before the therapy, serum IL-6 and plasma IL-8 levels were detectable in 77.8% and 28.5%, respectively, of patients with HCC. Levels of serum IL-6 and plasma IL-8 increased after TACE and reached a peak on day 3 in all patients (18/18) and in 87.5% of patients (12/14), respectively. Both blood levels of IL-6 and IL-8 reached a peak earlier than those of CRP and PSTI did after the therapy. When the maximal values of IL-6 were compared with those of CRP and PSTI, there were significant positive correlations (r = 0.63, P < 0.01 and r = 0.81, P < 0.01, respectively). Similarly, comparisons of the maximal values of IL-8 with those of CRP and PSTI gave a significant correlation (r = 0.68, P < 0.01 and r = 0.67, P < 0.05, respectively). However, no significant correlation was found between the elevation of IL-6 and IL-8.
authors.affiliation: Department of Surgery II, Kumamoto University Medical School, NTT Kyushu Hospital, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ikei
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Beppu
authors.forename: C
authors.initials: C
authors.lastname: Ohara
authors.forename: K
authors.initials: K
authors.lastname: Sakamoto
authors.forename: H
authors.initials: H
authors.lastname: Sameshima
authors.forename: H
authors.initials: H
authors.lastname: Arakawa
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: T
authors.initials: T
authors.lastname: Yamanaka
authors.forename: S
authors.initials: S
authors.lastname: Kudo
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000210:Acute-Phase Reaction / Q000097:blood / Q000209:etiology / Q000276:immunology; D002097:C-Reactive Protein / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000276:immunology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D016207:Cytokines / Q000097:blood*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood
chemical_list: D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D014359:Trypsin Inhibitor, Kazal Pancreatic; D015250:Aclarubicin; D002097:C-Reactive Protein; D002945:Cisplatin